PDE10A and Huntington disease: Despite the observed loss of PDE10A, PDE10 inhibition with the PF‐02545920 compound drives striatal cAMP and cGMP elevation, both of which are required to boost diminished corticostriatal input and indirect pathway output in symptomatic HD modelsPDE10A inhibition starting at presymptomatic ages mitigates the emergence of mHTT‐induced corticostriatal transmission deficits and aberrant striatal projecting neurons excitability